N/A
Completed N=356
Non-interventional Observational Study With Viramune (Nevirapine) and Various Drug Combinations in the Antiretroviral Combination Treatment of HIV-infected Patients Who Have Already Been Treated for Approx. 10 Years With Viramune
Source: ClinicalTrials.gov NCT00979420 ↗Enrolled (actual)
356
Serious AEs
9.8%
Results posted
Aug 2012
Primary outcomePrimary: Change in log10 Viral Load From Baseline to Last Visit — -3.260; -0.099; -2.082 log10 copies/ml
Summary
The question that prompted this study is the extent to which results from clinical trials can be translated into everyday practice (external validity). An observation period of about 10 years extends far beyond the duration of clinical trials. First and foremost are questions about tolerability and the efficacy of an antiretroviral combination treatment with Viramune and other antiretroviral partners. In particular, adverse events will be recorded and the therapeutic effect will be monitored via the course of viral load and improvement of the immune system, based on the CD4 cell count.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in log10 Viral Load From Baseline to Last Visit |
-3.284; 0.000; -2.000 | — |
| PRIMARY Number of Participants With Viral Load <50 Copies/ml and >=50 Copies/ml at Last Visit |
62; 33; 30; 1; 1; 3 | — |
| PRIMARY Change in Absolute CD4 Lymphocytes (CD4+) Cells From Baseline to Last Visit |
380; 223.5; 228 | — |
| PRIMARY Change in Absolute CD4 Lymphocytes (CD4+ Cells) From Baseline to Last Visit |
392; 283; 250 | — |
| SECONDARY Number of Patients With Laboratory Abnormalities for Cholesterol During Study (Worst Grade) by Division of AIDS (DAIDS) Grade |
11; 7; 4; 2; 26; 8 | — |
| SECONDARY Number of Patients With Laboratory Abnormalities for Low-density Lipoprotein (LDL) Cholesterol During Study (Worst Grade) by DAIDS Grade |
17; 9; 5; 9; 30; 6 | — |
| SECONDARY Number of Patients With Laboratory Abnormalities for Triglycerides During Study (Worst Grade) by DAIDS Grade |
72; 27; 17; 26; 0; 0 | — |
| SECONDARY Number of Patients With Laboratory Abnormalities for Blood Glucose During Study (Worst Grade) by DAIDS Grade |
50; 22; 21; 12; 83; 25 | — |
| SECONDARY Number of Patients With Laboratory Abnormalities for Alanine Aminotransferase (ALT) During Study (Worst Grade) by DAIDS Grade |
94; 32; 27; 28; 68; 17 | — |
| SECONDARY Number of Patients With Laboratory Abnormalities for Aspartate Aminotransferase (AST) During Study (Worst Grade) by DAIDS Grade |
105; 40; 40; 30; 58; 12 | — |
| SECONDARY Number of Patients With Laboratory Abnormalities for Creatinine During Study (Worst Grade) by DAIDS Grade |
152; 51; 50; 49; 13; 3 | — |
| SECONDARY Number of Patients With Laboratory Abnormalities for Hemoglobin During Study (Worst Grade) by DAIDS Grade |
171; 53; 58; 54; 6; 1 | — |
| SECONDARY Duration of Intake of Viramune |
131; 124; 131; 129 | — |
| SECONDARY History of Therapy With Antiretroviral Medication |
178; 0; 0; 0; 0; 57 | — |
| SECONDARY Course of Absolute CD4+ Cell Count |
734; 669; 491 | — |
| SECONDARY Number of Participants With Drug Related Adverse Events |
0; 0; 1; 0 | — |
Eligibility Criteria
Inclusion criteria The inclusion criteria for treatment with Viramune plus other antiretroviral combination drugs are to be based on the current Information for Healthcare Professionals/SPC (R08-0843)
Exclusion criteria The exclusion criteria for treatment with Viramune plus other antiretroviral combination drugs are to be based on the current Information for Healthcare Professionals/SPC (R08-0843).
Data sourced from ClinicalTrials.gov (NCT00979420). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.